The relationship between introduction of American Society of Clinical Oncology guidelines and the use of colony-stimulating factors in clinical practice in a Paris university hospital

Clinical Therapeutics

Volumn 23, Issue 7, 2001, Pages 1116-1127

  Debrix, Isabelle ^a   Tilleul, Patrick ^b   Milleron, Bernard ^a   Grené, Nathalie ^b   Bouleuc, Carole ^a   Roux, Dominique ^c   Lioté, Huguette ^a   Madelaine, Isabelle ^d   Bellanger, Agnès ^e   Conort, Ornella ^f   Fontan, Jean Eudes ^g   Le Mercier, Frank ^h   Bardin, Christophe ⁱ   Becker, Annie ^a  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f université Paris Cité   (France)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h HÔPITAL AMBROISE PARÉ   (France)

ⁱ HÔTEL DIEU   (France)

Author keywords

American Society of Clinical Oncology guidelines; Colony stimulating factors; Drug utilization study; Impact; Patient specific reminder

Indexed keywords

COLONY STIMULATING FACTOR;

ARTICLE; CONTINUING EDUCATION; DRUG UTILIZATION; FRANCE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRESCRIPTION; UNIVERSITY HOSPITAL;

EID: 0034894701     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80095-3     Document Type: Article

References (32)

1. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians
2. Practice guidelines: A new reality in medicine. III: Impact on patient care
3. Clinical practice guidelines on trial
4. Clinical decision making: From theory to practice. The individual vs society: Is there a conflict?
5. Clinical decision making: From theory to practice. Guidelines for policy statements: The explicit approach
6. Why don't physicians follow clinical practice guidelines? A framework for improvement
7. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines
8. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
9. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
10. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells
11. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial
12. Use of hematopoietic colony-stimulating factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines
13. Granulocyte growth factors: Achieving a consensus
14. Haematopoietic growth factors and cancer therapy
15. Implementing clinical practice guidelines: Can guidelines be used to improve medical practice?
16. Effect of clinical guidelines on medical practice: A systematic review of rigorous evaluations
17. Achieving health gain through clinical guidelines. II: Ensuring guidelines change medical practice
18. Methodology and reports of systematic reviews and meta-analyses. A comparison of Cochrane reviews with articles published in paper-based journals
19. Analysis of hematopoietic growth factor prescriptions in 19 French cancer centers
20. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer
21. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer
22. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity
23. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
24. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
25. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial
26. Randomized multicenter trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
27. Primary salvage treatment of recurrent germ cell tumors: Experience at Indiana University
28. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy
29. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia
30. Some aspects of the design and analysis of cluster randomisation trials
31. Multicenter study of the impact of prescription guidelines on the use of colony stimulating factors